CN120037232A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN120037232A
CN120037232A CN202510038924.9A CN202510038924A CN120037232A CN 120037232 A CN120037232 A CN 120037232A CN 202510038924 A CN202510038924 A CN 202510038924A CN 120037232 A CN120037232 A CN 120037232A
Authority
CN
China
Prior art keywords
weeks
bid
formula
mdm2 inhibitor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510038924.9A
Other languages
English (en)
Chinese (zh)
Inventor
W·罗思鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katos Medical Co
Original Assignee
Katos Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katos Medical Co filed Critical Katos Medical Co
Publication of CN120037232A publication Critical patent/CN120037232A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202510038924.9A 2018-04-30 2019-04-30 治疗癌症的方法 Pending CN120037232A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862664673P 2018-04-30 2018-04-30
US62/664673 2018-04-30
US201862701088P 2018-07-20 2018-07-20
US62/701088 2018-07-20
US201862781942P 2018-12-19 2018-12-19
US62/781942 2018-12-19
US201962834848P 2019-04-16 2019-04-16
US62/834848 2019-04-16
PCT/US2019/029906 WO2019213074A1 (en) 2018-04-30 2019-04-30 Methods of treating cancer
CN201980043405.4A CN112512525A (zh) 2018-04-30 2019-04-30 治疗癌症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980043405.4A Division CN112512525A (zh) 2018-04-30 2019-04-30 治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN120037232A true CN120037232A (zh) 2025-05-27

Family

ID=68386769

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510038924.9A Pending CN120037232A (zh) 2018-04-30 2019-04-30 治疗癌症的方法
CN201980043405.4A Pending CN112512525A (zh) 2018-04-30 2019-04-30 治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980043405.4A Pending CN112512525A (zh) 2018-04-30 2019-04-30 治疗癌症的方法

Country Status (20)

Country Link
US (2) US12115153B2 (cg-RX-API-DMAC10.html)
EP (1) EP3787625A4 (cg-RX-API-DMAC10.html)
JP (2) JP2021523220A (cg-RX-API-DMAC10.html)
KR (2) KR20250130704A (cg-RX-API-DMAC10.html)
CN (2) CN120037232A (cg-RX-API-DMAC10.html)
AU (2) AU2019263064B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020022148A2 (cg-RX-API-DMAC10.html)
CA (1) CA3098606A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020002833A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020014599A2 (cg-RX-API-DMAC10.html)
CR (1) CR20200576A (cg-RX-API-DMAC10.html)
IL (3) IL319432A (cg-RX-API-DMAC10.html)
JO (1) JOP20200273A1 (cg-RX-API-DMAC10.html)
MX (2) MX2020011608A (cg-RX-API-DMAC10.html)
PE (1) PE20211653A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020551820A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202010793UA (cg-RX-API-DMAC10.html)
TN (1) TN2020000210A1 (cg-RX-API-DMAC10.html)
TW (3) TWI741286B (cg-RX-API-DMAC10.html)
WO (1) WO2019213074A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022004225A2 (pt) * 2019-09-16 2022-05-31 Novartis Ag Uso de um inibidor de mdm2 para o tratamento de mielofibrose
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021175192A1 (en) * 2020-03-02 2021-09-10 Ascentage Pharma (Suzhou) Co., Ltd. Treatment methods and biomarkers for mdm2 inhibitors
WO2022219128A1 (en) * 2021-04-15 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) In vitro tests allowing to identify the potential for mdm2 inhibitors to induce the selection of mutations in patients suffering from a myeloproliferative neoplasm
EP4398903A4 (en) * 2021-09-09 2025-07-16 Kartos Therapeutics METHODS FOR TREATING CANCER DEPENDENT ON MYC GENE EXPRESSION
EP4398905A4 (en) * 2021-09-09 2025-07-16 Kartos Therapeutics METHODS OF TREATING CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
PT3456333T (pt) * 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
WO2014134201A1 (en) * 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
MA53572A1 (fr) * 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
KR102283895B1 (ko) * 2013-12-23 2021-07-30 노파르티스 아게 제약 조합물
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor

Also Published As

Publication number Publication date
IL278345B2 (en) 2024-05-01
JOP20200273A1 (ar) 2020-11-01
TW202146387A (zh) 2021-12-16
MX2024003655A (es) 2024-04-15
SG11202010793UA (en) 2020-11-27
WO2019213074A1 (en) 2019-11-07
US20250090517A1 (en) 2025-03-20
EP3787625A1 (en) 2021-03-10
CR20200576A (es) 2021-04-30
TW202529759A (zh) 2025-08-01
AU2019263064B2 (en) 2024-12-19
IL308399B2 (en) 2025-08-01
KR20210019422A (ko) 2021-02-22
IL278345A (cg-RX-API-DMAC10.html) 2020-12-31
PH12020551820A1 (en) 2021-07-26
MX2020011608A (es) 2021-02-17
IL308399B1 (en) 2025-04-01
TW201945340A (zh) 2019-12-01
KR102849513B1 (ko) 2025-08-25
BR112020022148A2 (pt) 2021-04-13
CN112512525A (zh) 2021-03-16
IL308399A (en) 2024-01-01
TN2020000210A1 (en) 2022-07-01
AU2025201686A1 (en) 2025-03-27
CL2020002833A1 (es) 2021-04-30
CA3098606A1 (en) 2019-11-07
EP3787625A4 (en) 2022-01-26
AU2019263064A1 (en) 2020-12-03
IL319432A (en) 2025-05-01
JP2021523220A (ja) 2021-09-02
IL278345B1 (en) 2024-01-01
US12115153B2 (en) 2024-10-15
CO2020014599A2 (es) 2021-02-26
KR20250130704A (ko) 2025-09-02
PE20211653A1 (es) 2021-08-24
TWI741286B (zh) 2021-10-01
US20210186946A1 (en) 2021-06-24
JP2024050668A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
KR102849513B1 (ko) 암 치료 방법
JP2025134754A (ja) Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類
KR20180113976A (ko) 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
JP2025072429A (ja) 骨髄増殖性腫瘍を治療する方法
CN107683138A (zh) 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途
EP4000624A1 (en) Btk inhibitors for treating splenomegaly
TW202128156A (zh) 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
EP2922827A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
EP4662319A2 (en) Personalized crispr profiling for cancer
CN121752272A (zh) 治疗骨髓增生性肿瘤的方法
US20240024314A1 (en) Methods of Treating Splenomegaly
KR20240144146A (ko) Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
EA045240B1 (ru) Способы лечения рака
HK40078282A (en) Btk inhibitors for treating splenomegaly
TW202532073A (zh) 以N-(4-(4-胺基-6-乙炔基-5-(喹啉-3-基)-7H-吡咯并[2, 3-d]嘧啶-7-基)雙環[2. 2. 1]庚烷-1-基)-5-甲基吡-2-甲醯胺或其鹽為有效成分之腦移行性腫瘤治療劑
WO2026102277A1 (en) Combination therapies comprising ikzf2 degrader compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination